CN Patent

CN101365676B — 作为用于治疗增生性疾病的mek抑制剂的吖丁啶

Assigned to Exelixis Inc · Expires 2013-09-11 · 13y expired

What this patent protects

本申请公开了式(I)的化合物及其药物可接受盐和溶剂合物。这类化合物是MEK抑制剂并可用于治疗增生性疾病，例如癌症。本申请还公开了含有这类化合物的药物组合物以及使用本发明的化合物和组合物治疗癌症的方法。

USPTO Abstract

本申请公开了式(I)的化合物及其药物可接受盐和溶剂合物。这类化合物是MEK抑制剂并可用于治疗增生性疾病，例如癌症。本申请还公开了含有这类化合物的药物组合物以及使用本发明的化合物和组合物治疗癌症的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN101365676B
Jurisdiction
CN
Classification
—
Expires
2013-09-11
Drug substance claim
No
Drug product claim
No
Assignee
Exelixis Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.